We have received your feedback.Thank you for taking your time in view of your busy schedule.
| Weekly News | Amount |
|---|---|
|
Total
|
${lastRankDetail.pages.length} |
| Financing | ${lastRankDetail.financing_pages.length} |
| Product | ${lastRankDetail.product_pages.length} |
| Negative | ${lastRankDetail.sentiment_pages.length} |
RecBio is a research and development company of genetic engineering vaccine for major diseases, which is committed to the innovation and industrialization of genetic engineering vaccine for major diseases, and has an innovative research and development technology platform for protein engineering and new adjuvant technology. At present, RuiKeShengWu has several product lines with market capacity of tens of billions represented by HPV series vaccines, recombinant herpes zoster virus vaccines, tuberculosis vaccines and recombinant COVID-19 vaccines, which are in different research and development stages
Transactions
Research
Competition
Transactions
Funding
1 Fundings
| Date | Amount | Round | Relative News |
|---|---|---|---|
| Nov 2020 | 100 million USD | Series B | First launch | RuiKeShengWu won over $100 million in Series B financing and more than 10 VC/PE investments |
Signals
Events
${currentEventsPage.count} Events
| Events (${currentEventsPage.count}) | Date |
|---|---|
| Nothing Happens :-( | |
| ${e.desp} | ${e.date} |
News
${ rankDetail.pages.length } News Articles
${currentTimeRange.start} ~ ${currentTimeRange.end}
| Article (${rankDetail.pages.length}) | Tag |
|---|---|
| ${article.en_title} | ${article.tag} |
Industry Financing Info
Research
Intelligence
0 Research Briefs
Competition
Competitors
0 Competitors
